Cargando…
ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling
BACKGROUND: Lung cancer (LC) is still the most common cause of cancer related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all LC cases but is not a single entity. It is now accepted that, apart from the characteristic driver mutations, the unique molecular signatures of...
Autores principales: | Vesel, M., Rapp, J., Feller, D., Kiss, E., Jaromi, L., Meggyes, M., Miskei, G., Duga, B., Smuk, G., Laszlo, T., Karner, I., Pongracz, J.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364604/ https://www.ncbi.nlm.nih.gov/pubmed/28340578 http://dx.doi.org/10.1186/s12931-017-0537-6 |
Ejemplares similares
-
Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility
por: Rapp, J., et al.
Publicado: (2016) -
WNT signaling – lung cancer is no exception
por: Rapp, Judit, et al.
Publicado: (2017) -
KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer
por: Jaromi, Luca, et al.
Publicado: (2021) -
Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
por: Papp, Emoke, et al.
Publicado: (2020) -
OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)